Zhengye Biotechnology Holding Limited
ZYBT
$6.70
-$2.79-29.40%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -13.61% | -20.99% | -28.03% | -25.20% | -22.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -13.61% | -20.99% | -28.03% | -25.20% | -22.49% |
| Cost of Revenue | -0.76% | -12.47% | -23.53% | -19.90% | -16.26% |
| Gross Profit | -23.88% | -27.59% | -31.43% | -29.04% | -26.85% |
| SG&A Expenses | 0.53% | -8.37% | -16.99% | -19.15% | -21.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.17% | -9.91% | -19.70% | -18.92% | -18.17% |
| Operating Income | -64.37% | -57.58% | -53.27% | -43.88% | -35.12% |
| Income Before Tax | -67.89% | -58.52% | -52.24% | -43.05% | -34.61% |
| Income Tax Expenses | -85.64% | -54.49% | -29.90% | -28.42% | -27.11% |
| Earnings from Continuing Operations | -64.95% | -59.15% | -55.51% | -45.19% | -35.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 65.18% | 59.42% | 55.82% | 45.39% | 35.80% |
| Net Income | -64.90% | -59.09% | -55.44% | -45.15% | -35.69% |
| EBIT | -64.37% | -57.58% | -53.27% | -43.88% | -35.12% |
| EBITDA | -42.33% | -40.13% | -39.07% | -30.83% | -22.72% |
| EPS Basic | -64.96% | -59.13% | -55.51% | -45.23% | -35.72% |
| Normalized Basic EPS | -68.63% | -58.45% | -51.52% | -42.86% | -34.81% |
| EPS Diluted | -64.96% | -59.13% | -55.51% | -45.23% | -35.72% |
| Normalized Diluted EPS | -68.63% | -58.45% | -51.52% | -42.86% | -34.81% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 0.14% | 0.94% | 2.07% | 1.80% | 1.69% |